Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total sales.
| Website: | www.novartis.com |
| Email: | Investor.relations@novartis.com |
| Main Phone: | +41 613241111 |
| Address: | Lichtstrasse 35 |
| City / Town: | Basel |
| Country: | CH |
| Postal Code: | 4056 |
| Exchange: | NYE |
| CEO: | Vasant Narasimhan |
| Employees: | 103914 |
| Issuer Type: | CS - Common Stock |
| Sector/Industry: | Cyclical |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Unlike green bonds which are linked to specific environmental projects, sustainability-linked bonds are tied to whole corporate goals.
Ofatumumab was approved by the FDA in 2009 for chronic lymphocytic leukaemia (CLL). It will be marketed as Kesimpta for multiple sclerosis.
90% of all prescriptions involve generics, medications that no longer hold patent protetection.
CEO Vas Narasimhan said the "extremely disruptive environment" of the pandemic would lead to mid-single digit percentage revenue growth for the full year, down from previous expectations of mid-to-high single-digit growth.
Novartis said it would provide medicines ranging from antibiotics and steroids to diarrhea pills to 79 countries on the World Bank’s list of low- and lower-middle income nations.
The moves further dampen hopes for a treatment that has been consistently and loudly touted by Trump as a gamechanger.
Artificial intelligence points to a rheumatoid arthritis drug that may be a viable treatment for the new virus.
How do we say that a drug costs “too much” when it can save or significantly extend a person’s life?
80 million annual exams in the US involve mydriasis (pupil dilation)
First transdermal product for this fast growing generic manufacturer (Image: Amneal Pharmaceuticals).
Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total sales.
| Website: | www.novartis.com |
| Email: | Investor.relations@novartis.com |
| Main Phone: | +41 613241111 |
| Address: | Lichtstrasse 35 |
| City / Town: | Basel |
| Country: | CH |
| Postal Code: | 4056 |
| Exchange: | NYE |
| CEO: | Vasant Narasimhan |
| Employees: | 103914 |
| Issuer Type: | CS - Common Stock |
| Sector/Industry: | Cyclical |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Unlike green bonds which are linked to specific environmental projects, sustainability-linked bonds are tied to whole corporate goals.
Ofatumumab was approved by the FDA in 2009 for chronic lymphocytic leukaemia (CLL). It will be marketed as Kesimpta for multiple sclerosis.
90% of all prescriptions involve generics, medications that no longer hold patent protetection.
CEO Vas Narasimhan said the "extremely disruptive environment" of the pandemic would lead to mid-single digit percentage revenue growth for the full year, down from previous expectations of mid-to-high single-digit growth.
Novartis said it would provide medicines ranging from antibiotics and steroids to diarrhea pills to 79 countries on the World Bank’s list of low- and lower-middle income nations.
The moves further dampen hopes for a treatment that has been consistently and loudly touted by Trump as a gamechanger.
Artificial intelligence points to a rheumatoid arthritis drug that may be a viable treatment for the new virus.
How do we say that a drug costs “too much” when it can save or significantly extend a person’s life?
80 million annual exams in the US involve mydriasis (pupil dilation)
First transdermal product for this fast growing generic manufacturer (Image: Amneal Pharmaceuticals).
| Last Price 86.30 | Change $ -1.15 | Change % -1.32 | Tick N/A |
| Bid 85.10 | Bid Size 100.00 | Ask 87.60 | Ask Size 100.00 |
| Open 86.66 | High 86.93 | Low 85.85 | Prev Close 87.45 |
| Last Trade | Volume 1.6 mi | 52 Wk Hi 99.85 | 52 Wk Low 69.19 |
| Market Cap 197.5 bi | Ex-Div Date | Div Rate 3.09 | Yield 3.3950 |
| Shares 2,288,979,612.00 | EPS (TTM) 5.28 | PE Ratio 28.50 | Exchange NYSE |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 98 | 98 | 98 | 98 |
| Low Target Price Estimate | 82.3 | 82.3 | 82.3 | 82.3 |
| Mean Target Price Estimate | 90.77 | 90.77 | 90.77 | 90.15 |
| Standard Deviation | 7.92 | 7.92 | 7.92 | 11.1 |
| Date of Most Recent Estimate | 04/23/18 | 04/23/18 | 04/23/18 | 04/23/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 4 | 2018-06-01 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 6 | 2018-06-01 |
| SD | Specialized Disclosure Report | 8 | 2018-05-31 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 6 | 2018-05-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 5 | 2018-05-16 |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-05-15 |
| SC TO-T/A | Amendment to a previously filed SC TO-T | 7 | 2018-05-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-11 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 |
| Moderate Sell | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 |
| Mean Rec. | 2.8 | 2.8 | 2.8 | 2.5 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait